222 related articles for article (PubMed ID: 31783700)
1. MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer.
Nishiuchi A; Hisamori S; Sakaguchi M; Fukuyama K; Hoshino N; Itatani Y; Honma S; Maekawa H; Nishigori T; Tsunoda S; Obama K; Miyoshi H; Shimono Y; Taketo MM; Sakai Y
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31783700
[TBL] [Abstract][Full Text] [Related]
2. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
3. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
4. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-675-5p Overexpression Is an Independent Prognostic Molecular Biomarker of Short-Term Relapse and Poor Overall Survival in Colorectal Cancer.
Christodoulou S; Sotiropoulou CD; Vassiliu P; Danias N; Arkadopoulos N; Sideris DC
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373137
[TBL] [Abstract][Full Text] [Related]
6. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
[TBL] [Abstract][Full Text] [Related]
7. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
8. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
[TBL] [Abstract][Full Text] [Related]
9. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
10. Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.
Okuda Y; Shimura T; Yamada T; Hirata Y; Yamaguchi R; Sakamoto E; Kataoka H
Int J Clin Oncol; 2018 Dec; 23(6):1101-1111. PubMed ID: 29948240
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of MALAT1 and miR-619-5p as a prognostic indicator in advanced colorectal carcinoma.
Qiu G; Zhang XB; Zhang SQ; Liu PL; Wu W; Zhang JY; Dai SR
Oncol Lett; 2016 Dec; 12(6):5036-5042. PubMed ID: 28101234
[TBL] [Abstract][Full Text] [Related]
13. Pattern of expression of CDX2 in colorectal cancer and its role in prognosis.
Singh J; Rajesh NG; Dubashi B; Maroju NK; Ganesan P; Matta KK; Charles I; Kayal S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S420-S427. PubMed ID: 36510997
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
15. CDX2 Is a Prognostic Biomarker for Unresectable Metastatic Colorectal Cancer.
Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
[TBL] [Abstract][Full Text] [Related]
16. GADD45B as a Prognostic and Predictive Biomarker in Stage II Colorectal Cancer.
Zhao Z; Gao Y; Guan X; Liu Z; Jiang Z; Liu X; Lin H; Yang M; Li C; Yang R; Zou S; Wang X
Genes (Basel); 2018 Jul; 9(7):. PubMed ID: 30029519
[No Abstract] [Full Text] [Related]
17. Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
Tsukamoto M; Iinuma H; Yagi T; Matsuda K; Hashiguchi Y
Oncology; 2017; 92(6):360-370. PubMed ID: 28376502
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
19. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
Li J; Zeng Q; Lin J; Huang H; Chen L
Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
[TBL] [Abstract][Full Text] [Related]
20. MiR-3614-5p Is a Potential Novel Biomarker for Colorectal Cancer.
Han L; Sun Y; Lu C; Ma C; Shi J; Sun D
Front Genet; 2021; 12():666833. PubMed ID: 34127929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]